BORON-CONTAINING SMALL MOLECULES

• US 20110212918A1
• Filed: 11/11/2010
• Published: 09/01/2011
• Est. Priority Date: 11/11/2009
• Status: Abandoned Application

• Current Assignee: Anacor Pharmaceuticals, Inc. (Pfizer Inc.)
• Original Assignee: Anacor Pharmaceuticals, Inc. (Pfizer Inc.)
• Inventors: Liu, Yang, Kevin Alley, Michael Richard, Zhang, Yanchen, Hernandez, Vincent S., Li, Xianfeng, Nieman, James A., Zhang, Suoming, Akama, Tsutomu, Plattner, Jacob J., Zhou, Yasheen
• Application Number:
  US12/944,699
• Publication Number:
  US 20110212918A1
• Time in Patent Office: Days
• US Class Current: 514/64
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: C07F 5/025 Boronic and borinic acid compounds

Abstract

This invention relates to, among other items, 6-substituted benzoxaborole compounds and their use for treating bacterial infections.

Claims

1. A compound, or a salt thereof, having a structure which is

2. The compound of claim 1, having a structure which is

3. The compound of claim 1, having a structure which is

4. The compound of claim 1, having a structure which is

5. A combination comprising:

a) a compound of claim 1, or a pharmaceutically acceptable salt thereof; and

b) a therapeutically active agent.

6. A pharmaceutical formulation comprising:

a) a compound of claim 1 or a combination of claim 5, or a pharmaceutically acceptable salt thereof; and

b) a pharmaceutically acceptable excipient.

7. The pharmaceutical formulation of claim 6, wherein said formulation is a unit dosage form.

8. The pharmaceutical formulation of claim 6, wherein said formulation is a member selected from an oral unit dosage form and a topical unit dosage form.

9. A method of killing or inhibiting the growth of a bacteria, said method comprising:

contacting said bacteria with an effective amount of a compound of claim 1 or a combination of claim 5, or a pharmaceutically acceptable salt thereof, thereby killing or inhibiting the growth of the bacteria.

10. A method of treating a bacterial infection comprising:

administering to an animal suffering from said infection an effective amount of a compound of claim 1, or a pharmaceutically-acceptable salt thereof, thereby treating the bacterial infection.

11. The method of claim 10, wherein said animal is a human.

12. A method of inhibiting the editing domain of a t-RNA synthetase, comprising:

contacting the synthetase with an effective amount of a compound of claim 1, or a pharmaceutically-acceptable salt thereof, thereby inhibiting the synthetase.

13. The method of claim 12, wherein the synthetase is a leucyl t-RNA synthetase.

14. The use of a compound of claim 1 or a combination of claim 6 or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment and/or prophylaxis of bacterial infection.